سعر ميثوتريكسات 5جم/50مل فيال 2025

Methotrexate-Ebewe 5 g/50 ml (100 mg/ml) concentrate in a single vial (Sandoz, marketed through Novartis Scientific Office), for high-dose cancer chemotherapy after dilution.

• Acute lymphocytic leukaemia; non-Hodgkin lymphomas; osteogenic sarcoma; adjuvant and advanced breast cancer; metastatic or recurrent head and neck cancer; choriocarcinoma and similar trophoblastic diseases; advanced cancer of the urinary bladderPopulation: Adults and paediatric patients (per protocols)Health Products Regulatory Authority (HPRA), Ireland

• Hypersensitivity; severe liver impairment; alcohol abuse; severe renal impairment (creatinine clearance below 20 ml/min); pre-existing blood dyscrasias (bone marrow hypoplasia, leukopenia, thrombocytopenia or significant anaemia); serious acute or chronic infections such as tuberculosis and HIV; oral ulcers and active gastrointestinal ulcer disease; breast-feeding; concurrent live vaccines.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Fatal toxicity has been reported after intravenous administration of incorrectly calculated doses; particular care is needed when calculating the dose.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Proton pump inhibitorsCo-administration with PPIs, especially with high-dose methotrexate, may delay methotrexate elimination and increase toxicity; use caution.Health Products Regulatory Authority (HPRA), Ireland

• Contraindicated in pregnancy in non-oncological indications. Low-dose exposure (<30 mg/week) has been associated with spontaneous abortion in 42.5% of exposed pregnant women (vs 22.5% in disease-matched controls) and major birth defects in 6.6% of live births (vs about 4%). In oncological indications it should not be used in pregnancy, especially the first trimester, unless benefit outweighs risk.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland
• Methotrexate passes into breast milk in amounts that pose a risk to the child even at therapeutic doses; breast-feeding must be discontinued before treatment.International label, equivalent formulation · Health Products Regulatory Authority (HPRA), Ireland

• Methotrexate: Folate analogue that inhibits dihydrofolic acid reductase, interfering with DNA synthesis, repair and cellular replication; actively proliferating tissues are most sensitive (US label).